Address
Pfizer Inc
235 East 42nd Street
150/39/18
New York, NY 10017
United States
Phone
Website
Sector
Recent investment activity
KANDO id: 4229
Funding rounds
Top investment portfolio themes
Actual initial investment stage
Acquisition (3)
Fund Closing (1)
Investment activity status
Active investor
Selected investments
Displaying 1 - 25 of 25Company | Profile | Country | Date | Funding | ||
---|---|---|---|---|---|---|
Ablexis LLC | Biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery. | N/A | ||||
BioRexis Pharmaceutical Corp | Acquisition | |||||
Celladon Corp | N/A | |||||
Coley Pharmaceutical Group Inc | N/A | |||||
DVS Sciences Inc | An analytical instrument and reagents company founded in Toronto | Series A | ||||
Esperion Therapeutics Inc | N/A | |||||
Excaliard Pharmaceuticals Inc | N/A | |||||
Five Prime Therapeutics Inc | N/A | |||||
Five Prime Therapeutics Inc | N/A | |||||
FoldRx Pharmaceuticals Inc | Acquisition | |||||
Icagen Inc | Biopharmaceutical company developing small molecule therapeutics that target ion channels for treatment of a variety of diseases. | Acquisition USD 56,000,000 (USD 56,000,000) | ||||
IDUN Pharmaceuticals Inc | Acquisition | |||||
Neuronetics Inc | Series E | |||||
NeuroTherapeutics Pharma Inc | N/A | |||||
Serenex Inc | Oncology-focused drug development company | Acquisition | ||||
TetraLogic Pharmaceuticals | A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. | Series C (USD 5,000,000) | ||||
Vicuron Pharmaceuticals Inc | Acquisition USD 1,900,000,000 (USD 1,900,000,000) | |||||
Anacor Pharmaceuticals Inc | Acquisition Initial investment led the round USD 5,200,000,000 (USD 5,200,000,000) | |||||
Avid Radiopharmaceuticals Inc | Series D | |||||
Avid Radiopharmaceuticals Inc | Series C | |||||
Avid Radiopharmaceuticals Inc | Series A | |||||
King Pharmaceuticals | Acquisition Initial investment led the round USD 3,600,000,000 (USD 3,600,000,000) | |||||
Medivation Inc | Acquisition USD 14,000,000,000 (USD 14,000,000,000) | |||||
Phoenix Venture Partners II LP | Venture capital fund focused on advanced materials startups. | Fund Closing Initial investment | ||||
Wyeth Pharmaceuticals | Acquisition Initial investment USD 68,000,000,000 (USD 68,000,000,000) |
Team
Employee | Position | |||
---|---|---|---|---|
Barbara J Dalton | Vice President
Venture Capital |
[email protected] |